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The clinical efficacy of one or two intravitreal injections of a continued deliverance dexamethasone 700𝜇g implant in ten
patients with persistent macular edema following uncomplicated phacoemulsification was evaluated. Complete ophthalmological
examination and spectral domain optical coherence tomography were carried out. Follow-up was at day 7 and months 1, 2, 4, 6,
8, and 12. At baseline mean best corrected visual acuity was 62 Early Treatment Diabetic Retinopathy Study Chart letters, which
showed statistically significant improvement at each follow-up, except at month 6, to reach 79 letters at month 12 (𝑃 = 0.018). Prior
to treatment mean central foveal thickness was 622𝜇m, which showed statistically significant improvement at each follow-up to
reach a mean value of 282 𝜇m (𝑃 = 0.012) at month 12. Five patients received a second dexamethasone implant at month 7. Two
patients were excluded from the study at months 4 and 8. Intraocular pressure remained stable during the study period with the
exception of mild increase in two patients requiring topical therapy. In conclusion there was statistically significant improvement of
best corrected visual acuity andmean central foveal thickness with one or two intravitreal dexamethasone implants over 12months.
1. Introduction
Cystoid macular edema (CME) or Irvine-Gass syndrome is
the main motive for inauspicious visual acuity achievement
following uncomplicated cataract extraction. The incidence
of CME after phacoemulsification is reported between 0.1 and
2% [1, 2]. Numerous factors have been held accountable in
the pathogenesis of CME but the phenomenon is still poorly
understood. However, it has been suggested that macular
edema arises due to increased vascular permeability follow-
ing surgical procedures such as cataract removal and pars
plana vitrectomy, which cause the release of prostaglandins
and disruption of the blood-retinal barrier [3, 4]. Corticos-
teroids, nonsteroidal anti-inflammatory agents, and carbonic
anhydrase inhibitors have been employed as common treat-
ment procedures [3–5]. Recently, intravitreal administration
of antivascular endothelial growth factor agents have also
been tested [6]. Treatment is recommended only in patients
with clinically significant macular edema, which is consid-
eredwhen visual acuity is 20/40 or less [7]. To date, there is no
standard treatment protocol for the management of chronic
pseudophakic CME.
Intravitreal pharmacological treatment has the advantage
of bypassing the blood-ocular barriers. Furthermore, due to
the particular anatomy of the eye, high intravitreal levels
of drug can be obtained and the efficacy of treatment
can be intensified by drug distribution close to the target
site. The dexamethasone implant (Ozurdex, Allergan Inc.,
Irvine, CA, USA) is an innovative treatment alternative for
noninfectious posterior uveitis and macular edema in retinal
vein occlusion [8]. Diabetic macular edema and, recently,
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prostaglandin-induced CME have also been treated with
agreeable results [9–11].This biodegradable implantmeasures
6.5mm × 0.45mm and is composed of a matrix consisting of
a copolymer of lactic and glycolic acids and dexamethasone
which dissolves completely into H
2
O and CO
2
leaving no
remnants. It is injected through the pars plana with a
monouse 22-gauge injector and postimplantation sutures
are not necessary. It furnishes continued deliverance of
dexamethasone where peak doses are supplied for 2 months
ensued by a slower release, altogether lasting for 6months and
providing 700𝜇g of dexamethasone [12].
The use of this implant has been reported in pseudopha-
kic CME with short-term follow-up [13–16]. To our knowl-
edge there are no reports of long-term results and the number
of implants necessary in the management of pseudophakic
CME. This study was carried out to evaluate the long-term
clinical efficacy of the dexamethasone intravitreal implant
in patients with persistent CME following uncomplicated
phacoemulsification.
2. Materials and Methods
In the present study we assessed 10 patients who were
diagnosed with CME due to decreased visual acuity and
increase in central foveal thickness (CFT) ensuing unremark-
able phacoemulsification. The patients were unresponsive to
topical steroids and nonsteroidal anti-inflammatory agents
and received treatment with the dexamethasone implant
at the Ophthalmology Unit of the St. Andrea Hospital,
University of Rome “Sapienza”. According to the declaration
of Helsinki, at the time of recruitment, informed consent to
take part in the study was read and signed by all patients.
Exclusion criteria comprised patients with diabetes,
uveitis, or other systemic diseases that could cause ocular
involvement, patients who had undergone precedent surgical
or parasurgical ocular procedures other than phacoemulsifi-
cation, vitreomacular traction with epiretinal membrane or
macular hole, age-related macular degeneration, retinal vas-
cular pathologies, glaucoma, or elevated IOP. Furthermore,
patients were also excluded if they were cortisone responders.
Cataract extraction was performed with the divide and
conquer technique and in-bag IOL implantation with no
complications. Clinically significant CME was classified as
visual acuity lower than 20/40 and CFT of more than 250𝜇m
persisting for a period longer than 90 days.
The method was similar to precedent studies on CME
(14–16) and the following were carried out for all patients:
ophthalmological examination comprising best corrected
visual acuity (BCVA) assessment using Early Treatment Dia-
betic Retinopathy Study (ETDRS) charts, ICare Tonometry
[17], and OCT evaluation using spectral domain optical
coherence tomography (SD-OCT) evaluation (Cross Line,
MM5, 3D Macular, RTVue SD-OCT) with CFT measure-
ment.
The intravitreal dexamethasone implant was injected in
the operating theatre through a biplanar intrascleral path
with a 22-gauge needle. All patients were then examined at
day 7 and months 1, 2, 4, 6, 8, and 12. Patients requiring
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Figure 1: Mean change in best corrected visual acuity (BVCA) from
baseline at each follow-up assessment.
a second injection of dexamethasone were implanted at
month 7.
2.1. Statistical Analysis. Statistical analysis was carried out
with SPSS software package V.21 (SPSS, Inc., Chicago, Illinois,
USA). Since the normality of data could not be assumed
because of the small sample size, the (nonparametric)
Wilcoxon signed-rank test was used to evaluate the differ-
ences in the median values of BCVA, CFT, and IOP between
baseline and day 7 andmonths 1, 2, 4, 6, 8, and 12. A 𝑃 value <
0.05 was considered significant, meaning that the median of
the difference (i.e., baseline day 7 or baseline month 6) is not
0.
3. Results
Tenpatientswith persistent pseudophakicCMEwho received
one or two implants of dexamethasone were selected. The
details regarding patient characteristics are given in Table 1.
The average persistence ofmacular edema before dexametha-
sone implantation was 3.1 months. One patient was excluded
from the study due to arterial occlusion at month 4 and a
second patient decided to discontinue follow-up at month 8.
Mean BCVA prior to treatment was 62 ETDRS letters.
Following implantation, statistically significant improvement
in BCVA was detected at day 7 and at each follow-up interval
with the exception of month 6.Three patients did not require
a second implant. In 5 eyes where visual acuity had declined
and foveal thickness had increased, a second implant was
injected at month 7. Mean BCVA was 79 ETDRS letters at 12
months (𝑃 = 0.018) (Table 1, Figure 1).
Prior to treatment the mean CFT was 622𝜇m; fol-
lowing dexamethasone implantation, statistically significant
improvement was seen at day 7 and at each follow-up interval
to improve to 282𝜇m (𝑃 = 0.012) at 12 months. A second
implant was injected at month 7 in 5 patients who showed
recurrence (Table 2, Figure 2).
Figure 3 shows optical coherence tomography images of
CFT change over time and results of a second implant in one
patient with recurrence.
There were two cases of intraocular pressure increase
>25mmHg, which were successfully managed with topical
timolol 0.5% and intraocular pressure remained stable during
the study period (Table 3).
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Table 1: Patient characteristics and best corrected visual acuity (BCVA) values in study eye using ETDRS charts prior to treatment and at
follow-up intervals.
Patient Gender Age Baseline Day 7 Mo. 1 Mo. 2 Mo. 4 Mo. 6 Mo. 8 Mo. 12
1 F 72 78 84 86 87 88 88 88 88
2 F 81 71 73 78 79 80 80 80 80
3§ M 78 36 58 70 78 — — — —
4§ M 77 35 36 73 78 49 36 — —
5 F 78 70 71 73 74 76 78 83 84
6∗ M 81 65 80 83 84 75 66 78 65
7∗ F 62 72 74 80 83 76 70 80 78
8∗ F 65 59 60 70 73 68 67 72 74
9∗ M 71 60 78 80 83 67 62 83 75
10∗ M 71 70 79 83 83 75 68 84 88
Mean 73.6 61.6 69.3 77.6 80.2 72.7 68.3 81 79
Median 74.5 67.5 73.5 79 81 75 68 81.5 79
SD 6.5 14.9 14.4 5.8 4.5 10.8 14.6 4.8 7.8
Range 62–81 35–78 36–84 70–86 73–87 49–88 36–88 72–88 65–8
𝑃 value† 0.005 0.005 0.005 0.008 0.084 0.011 0.018
Delta‡ 7.7 16 18.6 11.1 6.7 19.4 17.4
∗Patients denoted with ∗ had a second implant at month 7.
§Patients dropped out from the study.
†
𝑃 value refers to Wilcoxon signed-rank test on the median values with respect to the baseline.
‡Delta denotes the mean difference with the baseline.
Mo.: month.
Table 2: Central foveal thickness (CFT) prior to treatment and at follow-up intervals.
Patient Baseline Day 7 Mo. 1 Mo. 2 Mo. 4 Mo. 6 Mo. 8 Mo. 12
1 563 349 349 346 345 339 340 346
2 438 381 266 256 250 255 251 248
3§ 852 361 221 220 — — — —
4§ 707 395 223 215 260 470 — —
5 658 263 254 201 213 213 210 215
6∗ 630 312 279 266 295 309 250 369
7∗ 424 297 269 289 268 277 250 261
8∗ 808 397 270 263 278 280 273 268
9∗ 610 369 302 289 285 298 281 303
10∗ 526 331 305 289 290 293 282 249
Mean 621.6 345.5 273.8 263.4 276 303.8 267.1 282.4
Median 620 355 269.5 264.5 278 293 262 264.5
SD 142.2 44.3 38.5 43.4 36.0 71.5 37.5 52.7
Range 424–852 263–397 221–349 201–346 213–345 213–470 210–340 215–369
𝑃 value† 0.005 0.005 0.005 0.008 0.008 0.012 0.012
Delta‡ −276 −348 −358 −346 −318 −354 −339
∗Patients denoted with ∗ had a second implant at month 7.
§Patients dropped out from the study.
†
𝑃 value refers to Wilcoxon signed-rank test on the median values with respect to the baseline.
‡Delta denotes the mean difference with the baseline.
Mo.: month.
4. Discussion
In the present study on CME following uncomplicated pha-
coemulsification, mean BCVA and CFT improved following
one or two injections of intravitreal dexamethasone implants
over 12 months of follow-up. A second implant was required
in five eyeswhereas in three eyes results weremaintained after
only one implant throughout the follow-up period.
There have been few studies where the results of one
intravitreal injection of dexamethasone have been evaluated
with short-term follow-up in pseudophakic CME (13–16).
Analysis of 8 patients with Irvine-Gass syndrome showed
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Table 3: Intraocular pressure (mmHg) prior to treatment and at follow-up intervals.
Baseline Day 7 Mo. 1 Mo. 2 Mo. 4 Mo 6 Mo. 8 Mo. 12
1 17 14 14 14 14 14 13 14
2 11 16 13 13 13 13 13 13
3§ 14 17 16 13 — — — —
4§ 13 21 21 20 18t 14t — —
5 14 16 12 12 14 13 13 16
6∗ 14 16 14 16 16 18 18 16
7∗ 14 16 20 17t 18t 15t 16t 16t
8∗ 15 19 19 18 16 15 20 16
9∗ 15 17 16 17 17 16 16 14
10∗ 15 16 17 16 16 17 17 17
Mean 14.2 16.8 16.2 15.6 15.8 15 15.8 16
Median 14 16 16 16 16 15 16 16
SD 1.5 1.9 3.0 2.5 1.8 1.7 2.6 1.4
Range 11–17 14–21 12–21 12–20 13–18 13–18 13–20 13–17
𝑃 value† 0.031 0.120 0.165 0.091 0.228 0.158 0.222
Delta‡ 2.6 2.0 1.4 1.6 0.8 1.6 1.8
∗Patients denoted with ∗ had a second implant at month 7.
§Patients dropped out from the study.
†
𝑃 value refers to Wilcoxon signed-rank test on the median values with respect to the baseline.
‡Delta denotes the mean difference with the baseline.
tPatients who were prescribed topical intraocular pressure lowering medication.
Mo.: month.
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Figure 2: Mean change in central foveal thickness (CFT) from
baseline at each follow-up assessment.
improvement of both BCVA and macular edema at 90 days
from intravitreal injection of dexamethasone, which was
maintainedup to 180 days in 54%of eyes [13].This is similar to
our results where 50% of patients required a second implant
after 6 months. Furino et al. and Al Zamil analyzed eyes with
CME following uncomplicated phacoemulsification with a
mean duration of 2.4 and 7.7 months, respectively, where a
single injection of dexamethasone was performed and found
significant reduction of macular edema and improvement of
BCVA at 6 months [15, 16].
Medeiros et al. presented the outcome of a single dexam-
ethasone implant in 9 patients with Irvine-Gass syndrome
with a mean duration of 9.1 months. They reported peak
effectiveness of the implant at 3 months from treatment
and significant amelioration of macular thickness and BCVA
during 6 months of follow-up [14]. In our study mean peak
improvement of visual acuity was at 2 months following the
first implant and at 8 months following the second implant.
Mean peak improvement of CFT was at 2 months. Mean
BCVA significantly improved at each follow-up except at
month 6. According to the pharmacodynamics of the dex-
amethasone implant, this corresponds to the time when the
release of dexamethasone is largely terminated. Nevertheless,
at 12 months, following a second implant in 50% of patients,
BCVA was significantly improved. As regarding CFT, there
was a statistically significant improvement at each follow-up
and the trendwasmore stablewith respect to BCVA; however,
even here there was a slight increase in CFT at 6 months
(304 𝜇m).
Corticosteroids diminish the amount of intraocular
prostaglandins and other factors believed to have a role in
postoperative CME. In a prospective randomized controlled
trial Negi et al. compared topical and periocular corticos-
teroids following routine cataract surgery and found both
safe and effective routes of administration [18]. However,
topical and periocular administration have a short half-
life and have been reported to reach significant systemic
concentrations [19]. Intravitreal injection of triamcinolone
acetonide has been demonstrated to produce visual improve-
ment and reduction of CME [20, 21] but the use of tri-
amcinolone is limited due to the requirement of multi-
ple injections and the side effects in terms of increase in
intraocular pressure and cataract formation [22], although
even with the dexamethasone implant a repeat injection
was required in 50% of our cases. While dexamethasone
is a more potent corticosteroid, it has a shorter half-life,
which restricts its clinical efficacy as an injectable sus-
pension, thus the rationale for an implant with a contin-
ued deliverance method, which can provide drug release
through long periods with a minor frequency of adverse
effects.
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Figure 3: Optical coherence tomography of macular profile and thickness following dexamethasone implant at baseline and 7 months. (a)
Before treatment, (b) 2months following first dexamethasone implant, (c) 6months following first dexamethasone implant, and (d) 12months
following second dexamethasone implant at month 7.
In two patients there was an increase in IOP > 25 which
was successfully managed with topical treatment. This is
in agreement with the reported trend following intravitreal
dexamethasone administrationwhere IOP is increased in 15%
of patients with peak values at 60 days and returns to baseline
at 6 months [23]. Patient 3 had retinal artery occlusion
at month 4. We cannot be sure of the cause; however, in
the judgment of the authors, it is unlikely that there was
a reasonable possibility that this serious adverse effect was
caused by the dexamethasone implant, the applicator, or the
injection procedure. Furthermore, to our knowledge, arterial
occlusion has not been reported in large patient population
studies, which have also addressed the safety profile of the
dexamethasone implant [9, 24]. There were no cases of
cataract formation in any patient.
The limitations of our study were the retrospective
description, the modest number of eyes, and the absence
of a control group. The strength of our study was the long
follow-up, which demonstrated the necessity for a second
implant after 6 months in 50% of cases.
5. Conclusions
This is the first report on the long-term clinical results
of the dexamethasone intravitreal implant in patients pre-
senting CME following phacoemulsification. BCVA and
CFT significantly improved at 12 months of follow-up
although a second implant was required after 6 months
in 50% of cases. Therefore, our studies suggest that sin-
gle or multiple injections of the dexamethasone implant
are an effective treatment option for patients with persis-
tent CME ensuing uncomplicated cataract extraction with
phacoemulsification.
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